Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection

Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machiner...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Thomas L., Colzani, Maria T., Macrae, Robyn G. C., Robinson, Emma L., Bloor, Stuart, Greenwood, Edward J. D., Zhan, Jun Ru, Strachan, Gregory, Kuc, Rhoda E., Nyimanu, Duuamene, Maguire, Janet J., Lehner, Paul J., Sinha, Sanjay, Davenport, Anthony P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322398/
https://www.ncbi.nlm.nih.gov/pubmed/34326460
http://dx.doi.org/10.1038/s42003-021-02453-y
Descripción
Sumario:Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.

Ejemplares similares